Clinical Trial Update: Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating MEDI4736 (durvalumab) alone and in combination with tremelimumab versus standard of care in recurrent/metastatic PD-L1-positive or -Neg…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• MEDI4736 (Durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: AstraZeneca | Conditions: Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN | Phase 3 | Status: COMPLETED | Results posted: 2019-10-03